Literature DB >> 10430835

Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease.

K Meguro1, X Blaizot, Y Kondoh, C Le Mestric, J C Baron, C Chavoix.   

Abstract

Temporoparietal glucose hypometabolism, neuronal loss in the basal forebrain cholinergic structures and preferential accumulation of neurofibrillary tangles in the rhinal cortex (i.e. in the entorhinal and perirhinal cortices) are three early characteristics of Alzheimer's disease. Based on studies of the effects of neurotoxic lesions in baboons, we previously concluded that damage to the cholinergic structures plays, at best, a marginal role in the association neocortex hypometabolism of Alzheimer's disease. In the present study, we have assessed the remote metabolic effects of bilateral neurotoxic lesions of both entorhinal and perirhinal cortices. Using coronal PET coregistered with MRI, the cerebral metabolic rate for glucose (CMR(glc)) was measured before surgery and sequentially for 2-3 months afterward (around days 30, 45 and 80). Compared with sham-operated baboons, the lesioned animals showed a significant and long-lasting CMR(glc) decline in a small set of brain regions, especially in the inferior parietal, posterior temporal, posterior cingulate and associative occipital cortices, as well as in the posterior hippocampal region, all of which also exhibit glucose hypometabolism in Alzheimer's disease. Remarkably, the degree of CMR(glc) decline in four of these regions significantly correlated with the severity of histologically determined damage in the rhinal cortex, strongly supporting the specificity of the observed metabolic effects. There were also differences between the metabolic pattern observed in the lesioned animals and that classically reported in Alzheimer's disease; for instance, the hypometabolism we found in the stratum has not been reported in early Alzheimer's disease, although this structure can be affected in late stages of the disease and has direct anatomical connections with the rhinal cortex. Nevertheless, this study shows for the first time that the temporoparietal and hippocampal hypometabolism found in Alzheimer's disease may partly result from neuroanatomical disconnection with the rhinal cortex. This, in turn, further strengthens the hypothesis that neuronal damage and dysfunction in the rhinal cortices play a major role in the expression of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430835     DOI: 10.1093/brain/122.8.1519

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  62 in total

1.  Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).

Authors:  M J de Leon; A Convit; O T Wolf; C Y Tarshish; S DeSanti; H Rusinek; W Tsui; E Kandil; A J Scherer; A Roche; A Imossi; E Thorn; M Bobinski; C Caraos; P Lesbre; D Schlyer; J Poirier; B Reisberg; J Fowler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

2.  Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents.

Authors:  Lisa Mosconi; Juha O Rinne; Wai H Tsui; John Murray; Yi Li; Lidia Glodzik; Pauline McHugh; Schantel Williams; Megan Cummings; Elizabeth Pirraglia; Stanley J Goldsmith; Shankar Vallabhajosula; Noora Scheinin; Tapio Viljanen; Kjell Någren; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2012-04-11       Impact factor: 4.673

3.  Anterior thalamic lesions produce chronic and profuse transcriptional de-regulation in retrosplenial cortex: A model of retrosplenial hypoactivity and covert pathology.

Authors:  G L Poirier; K L Shires; D Sugden; E Amin; K L Thomas; D A Carter; J P Aggleton
Journal:  Thalamus Relat Syst       Date:  2008-03

Review 4.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

5.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.

Authors:  Eric M Reiman; Kewei Chen; Gene E Alexander; Richard J Caselli; Daniel Bandy; David Osborne; Ann M Saunders; John Hardy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

6.  Evaluation of frame-based and event-by-event motion-correction methods for awake monkey brain PET imaging.

Authors:  Xiao Jin; Tim Mulnix; Christine M Sandiego; Richard E Carson
Journal:  J Nucl Med       Date:  2014-01-16       Impact factor: 10.057

7.  Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford R Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett
Journal:  Alzheimers Dement       Date:  2005-07       Impact factor: 21.566

8.  Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance.

Authors:  Nikolaos Scarmeas; Christian G Habeck; Eric Zarahn; Karen E Anderson; Aileen Park; John Hilton; Gregory H Pelton; Matthias H Tabert; Lawrence S Honig; James R Moeller; Davangere P Devanand; Yaakov Stern
Journal:  Neuroimage       Date:  2004-09       Impact factor: 6.556

Review 9.  Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies.

Authors:  Bradford C Dickerson; Reisa A Sperling
Journal:  Neuropsychologia       Date:  2007-12-08       Impact factor: 3.139

10.  Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI.

Authors:  Michael D Greicius; Gaurav Srivastava; Allan L Reiss; Vinod Menon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.